The E2F1 transcription factor plays a pivotal role in driving cells out of a quiescent state and into the S phase of the cell cycle, in part by transactivating genes needed for DNA replication including DHFR, thymidine kinase, and DNA Polymerase a. E2F1 has also been implicated in regulating an S phase checkpoint, however its role in this checkpoint is not well de®ned. To determine how E2F1 aects such a checkpoint, we utilized an in vivo replication assay employing a plasmid based SV40 origin of replication, transfected into cells expressing SV40 large T antigen. Here we show that expression of full length E2F1, or only its N terminus, represses replication from plasmids containing the SV40 origin, while N terminal deletions of E2F1 do not. E2F1 appears to inhibit the elongation phase of replication and not the initiation phase since it does not aect the replication of other cotransfected plasmids containing only the SV40 origin. Further, inhibition of replication is dependent on both the amino-terminus of the E2F1 protein and on a DNA sequence that is contained within the 3' end of the E2F1 cDNA. Additionally, both full-length E2F1, or just its N-terminus, form protein complexes with two portions of the 3' end of the E2F1 cDNA. These data provide a clue to the mechanism by which E2F1 regulates transit through the S phase checkpoint, by acting on a speci®c DNA sequence via its amino-terminal region, to inhibit elongation of DNA replication.
Introduction
The E2F1 family of transcription factors plays an essential role in the transition from G 0 /G 1 to S phase of the mammalian cell cycle (Helin, 1998; Sherr, 1996) . E2F1 accomplishes this function by trans-activating the genes necessary for progression into and through S phase (DeGregori et al., 1995a; Helin, 1998; Ohtani, 1999) . These genes encode much of the machinery involved in deoxyribonucleotide biosynthesis and DNA replication, such as DHFR, thymidine kinase, DNA Polymerase a, ORC1, and CDC6 (DeGregori et al., 1995a; Helin, 1998; Ohtani, 1999) . Consistent with this ability to activate transcription, overexpression of E2F1 also has been shown to drive resting cells into S phase (Asano et al., 1996; DeGregori et al., 1995b; Johnson et al., 1993; Logan et al., 1994 Logan et al., , 1995 .
Analysis of functional domains within E2F1 has lead to an interesting ®nding regarding cell cycle transit. Mutants of E2F1 have been found to have an eect on the timing and duration of S phase. N-terminal deletions of E2F1, speci®cally deletions of the cyclin A/cdk2 binding domain, have been shown to cause an increase in S phase duration when expressed in cells (Krek et al., 1995; Logan et al., 1995) . It is still unclear how E2F1 regulates an S phase checkpoint, but the mechanism appears to require the association of cyclin A/cdk2 to regulate the phosphorylation state of E2F1. Phosphorylation of E2F1 causes its dissociation from DNA, which has been proposed to allow cells to complete S phase (Krek et al., 1995) . Therefore, cyclin A/cdk2 binding to E2F1 during S phase is necessary for cells to transit S phase properly. If cyclin A/cdk2 is unable to bind E2F1, E2F1 remains hypophosphorylated and bound to DNA, an S phase checkpoint is activated, cell cycle transit is slowed, and apoptosis will ensue (Krek et al., 1995) . Thus, cells expressing a mutant E2F1 lacking its ®rst 87 amino acids, and therefore lacking part of its cyclin A/cdk2 binding domain, have a prolonged S phase (Logan et al., 1995; Stubbs et al., 1999) . These cells are unable to pass through a checkpoint that occurs early in S phase and DNA replication is signi®cantly slowed.
To determine if E2F1 directly regulates DNA synthesis, its eect on DNA replication was analysed in an SV40 based system, since SV40 contains a very well characterized 64 bp origin of replication (Dean et al., 1987; Deb et al., 1986 Deb et al., , 1987 . Initiation of DNA replication at the SV40 origin requires far fewer proteins than are needed in higher eukaryotes. For example, only SV40 large T antigen (TAg), topoisomerase I (Topo I), RP-A (or single strand binding protein ± SSB), and the DNA polymerase a-primase complex are required for initiation (Bullock, 1997) . In contrast, higher eukaryotic DNA replication requires many more proteins for interaction at the origins, the latter of which are less well de®ned and usually spread over many kilobases (Bambara et al., 1997; Coverley and Laskey, 1994; DePamphilis, 1993a,b; Dutta and Bell, 1997; Stillman, 1994 Stillman, , 1996 . In addition, the structure and function of large T antigen at the SV40 origin has been well characterized (Bullock, 1997; Dean et al., 1987; Deb et al., 1987) while much remains to be discovered about higher eukaryotic origin binding proteins that are needed for initiation of replication. Here we show that expression of full length E2F1 in COS cells inhibits elongation, but not initiation of SV40 based DNA replication. Surprisingly, expression of only the N terminus of E2F1 is capable of inhibiting replication, acting through a DNA sequence contained within the E2F1 cDNA. The role of E2F1 in regulating DNA replication and transit through the S phase checkpoint will be discussed.
Results

E2F1 inhibits DNA replication through its N terminus
It has been previously shown that E2F1 is involved in the regulation of transit through an S phase checkpoint (Krek et al., 1995; Logan et al., 1995; Stubbs et al., 1999) . The N terminus of E2F1 appears to control this checkpoint function of E2F1, in part through its association with cyclin A/cdk2 (Krek et al., 1995) . In this regard it has been demonstrated that expression in cells of mutant E2F1's that lack the N terminus leads to an arrest in S phase (Krek et al., 1995; Logan et al., 1995; Stubbs et al., 1999) . It was our goal here to explore the role of E2F1 in the S phase checkpoint in more detail, with an emphasis on the N terminus of E2F1. To approach this problem, we made use of an SV40 origin based replication system. Plasmids containing an SV40 origin will replicate extrachromosomally in COS cells due to the presence of SV40 large T antigen in the cells (Chittenden et al., 1991) . It was our Figure 1 Plasmids expressing wild type E2F1 have diminished replication levels. COS cells were transfected with empty vector (pcDNA3), with the E2F1 expression plasmid or with plasmids expressing mutants of E2F1. Forty-eight hours after transfection, the cells were harvested and the plasmids were isolated by method of Hirt, 1967 . Two mg of plasmid were digested with HindIII and DpnI and electrophoresed in a 0.8% agarose gel. The gels were Southern blotted onto nylon membranes and probed with 32 Plabeled pcDNA3 plasmid. (a) Shown is a diagram of the full length E2F1 protein and the E2F1 mutants. The shaded regions indicate the major functional domains of the E2F1 protein. Each cDNA was Flag-tagged (E2F1D24 is HA tagged) at the very 5' end (N-terminus) and cloned into the pcDNA3 eukaryotic expression plasmid (InVitrogen). (b) Shown is a representative autoradiograph of the Southern blot indicating the levels of replicated plasmid. (c) Shown is the quantitation of the average relative levels (%) of replicated plasmid as determined by densitometry of autoradiographs (as in b) from multiple experiments. The level of pcDNA3 was arbitrarily set at 100%. Error bars represent the standard deviation of the mean. (d) COS cells grown on coverslips were transfected with empty vector (pcDNA3) or with the indicated E2F1 expression plasmids. Forty-eight hours after transfection, the cells were ®xed and prepared for¯uorescence microscopy, using either the M2 antiFlag or the anti-HA monoclonal antibodies followed by a FITC conjugated secondary antibody and DAPI stain for DNA. Shown are representative positive cells for each transfection supposition that expression of E2F1 N terminal deletion mutants in COS cells should aect the replication of plasmids due to the activation of an S phase checkpoint.
To begin these studies, plasmids expressing full length human E2F1, various E2F1 N terminal deletion mutants (see Figure 1a) , or the vector alone (pcDNA3) were transfected into COS cells, and 48 h later the plasmids were isolated from the cells by the Hirt method (Hirt, 1967) . The plasmids were digested with DpnI to remove any unreplicated plasmid (DpnI digests bacterial-methylated DNA only). Two mg of plasmid were then digested with HindIII, electrophoresed on agarose, and Southern blotted onto a nylon membrane. The blot was probed with a 32 P-labeled pcDNA3 plasmid. Shown in Figure 1b is an autoradiogram of the blot. It is clear that the plasmid expressing E2F1 replicates to a signi®cantly lower level (over ®vefold) than the vector control, which is quantitated in Figure  1c .
The eect of expression of N terminal deletion mutants of E2F1 on plasmid replication was also analysed. These deletion mutations of E2F1 are lacking their N terminal 59, 78, 87, and 103 amino acid residues (termed E2F1d59, E2F1d78, E2F1d87, and E2F1d103 respectively) as is depicted in Figure 1a . The E2F1d87 mutant protein partially deletes the cyclin A/ cdk2 binding domain (Jordan-Sciutto and Hall, 1998) , while E2F1d103 completely lacks this domain. As seen in Figure 1b , pcDNA3 plasmids expressing these E2F1 constructs replicate to levels equal to the plasmid backbone, as quantitated in Figure 1c . The data presented above indicate that ectopic expression of full length E2F1 in COS cells has a very potent inhibitory eect on SV40 based plasmid replication. In sharp contrast, E2F1 mutants lacking the N terminal portion of the protein do not have such an inhibitory eect.
To determine more accurately if the cyclin A/cdk2 binding domain is needed, we made use of another E2F1 mutant. Since the cyclin A/cdk2 binding domain of E2F1 is known to be located between amino acids 68 ± 108, E2F1 mutants have been generated that abolish cyclin A/cdk2 binding activity. One of these mutants, E2F1D24, is missing residues 79 ± 103 (shown in Figure 1a ) thereby abolishing cyclin A/cdk2 binding (Krek et al., 1995) . Figure 1c indicates that plasmids expressing the E2F1D24 mutant replicate to lower levels (approximately ®vefold) than that of backbone plasmid. The cyclin A/cdk2 binding domain, therefore, does not appear to play a role in the inhibition of DNA replication by E2F1, since deleting the domain does not restore plasmid replication to levels of backbone vector control.
To further implicate the N terminus of E2F1 in inhibition of plasmid replication, a mutant E2F1 was created consisting of only the ®rst 139 amino acids ( Figure 1a ). Another E2F1 mutant (termed 1 ± 415) was constructed where the last 22 amino acids were deleted, eliminating the transactivation and Rb binding domains of E2F1 (Figure 1a) . Thus, both E2F1(1 ± 139) and E2F1(1 ± 415) contain the N terminus of E2F1 and are unable to activate transcription (data not shown). The E2F1(1 ± 139) and E2F1(1 ± 415) cDNAs were cloned into pcDNA3. Both the 1 ± 139 and 1 ± 415 plasmids show impaired replication similar to that of wild type E2F1 (Figure 1c ). Since both of these plasmids express the N terminus of E2F1, this region seems sucient to cause inhibition of plasmid replication. These data combined with the earlier results indicate that the inhibitory region lies somewhere within the ®rst 59 amino acids of E2F1. Additionally, the data indicate that the cyclin A/cdk2 binding domain, the DNA binding domain, and the transactivation domain are not required for replication inhibition.
As controls for the above experiments, expression of the E2F1 constructs was detected by indirect immunouorescence as shown in Figure 1d . Since each E2F1 construct used in these studies was epitope tagged with an N terminal FLAG or HA (E2F1D24) sequence, an M2 or anti-HA antibody was used as a primary antibody, and a¯uorescein-conjugated anti-mouse antibody was utilized as a secondary antibody. The pcDNA3 transfected cells were completely negative for FITC¯uorescence. Figure 1d shows that the E2F1 proteins (wild type and mutant) are all ectopically expressed in COS cells and are targeted primarily to the nucleus.
One possibility for the inhibition of DNA replication of the E2F1 expression plasmid is that it is dependent on the G/C rich region at the very 5' end of the E2F1 cDNA (encoding the N terminus). The ®rst 417 basepairs are nearly 80% G/C, which could act as a thermodynamic clamp, preventing the DNA from denaturing rapidly during replication. To control for this possibility, a plasmid was constructed where the E2F1 cDNA cloned into the pcDNA3 expression Figure 2 The replication inhibition function of E2F1 is not dependent on the G/C rich DNA sequence within the 5' end of the E2F1 cDNA. COS cells were transfected with empty vector (pcDNA3), the E2F1 expression plasmid, plasmids expressing the MDMX or ZF87/MAZ proteins, or a plasmid containing the E2F1 cDNA in reverse orientation (E2F1REV). Plasmid isolation, Southern blotting, and densitometry of autoradiographs were carried out as in Figure 1 . Shown is the quantitation of the average relative levels (%) of replicated plasmid as determined by densitometry of autoradiographs from multiple experiments. pcDNA3 levels were arbitrarily set at 100%. Error bars represent the standard deviation of the mean vector in the opposite orientation of the pcDNA3 CMV immediate early promoter. This plasmid was termed E2F1REV. The entire E2F1 cDNA while present in the plasmid will not encode any E2F1 protein, but it does contain the G/C rich region. If G/C richness is a factor in replication, then this plasmid should be aected. This plasmid was transfected into COS cells and the replication assay was performed as described above. This plasmid also replicates to levels equal to the backbone plasmid, as seen in Figure 2 . These data indicate that the G/C content of the E2F1 cDNA is not playing a role in plasmid replication.
Another cDNA with a high G/C content, the ZF87/ MAZ transcription factor (Izzo et al., 1999; Pyrc et al., 1992) , was also used in this assay. Like the E2F1 cDNA, it also has an 80% G/C content within the ®rst 400 basepairs. The pcDNA3 plasmid containing the ZF87/MAZ construct replicated to levels equal to that of the backbone vector (Figure 2) , indicating that the G/C content of the plasmid is not a factor in its ability to replicate. It also indicates that replication inhibition is speci®c for E2F1. As an additional control, this experiment was repeated with a plasmid expressing the MDMX protein, a p53 interactive factor (Shvarts et al., 1996) , to further ensure that the eect seen above is speci®c for E2F1. As shown in Figure 2 , the MDMX expressing plasmid also replicated to levels of backbone vector indicating that MDMX has no aect on plasmid replication.
Apoptosis is not a factor in the change in plasmid replication levels
It was necessary to make sure that the eect of E2F1 on replication was not due to induction of apoptosis as has been described for some cell types (Asano et al., 1996; DeGregori et al., 1997; Field et al., 1996; Hsieh et al., 1997; Kowalik et al., 1995 Kowalik et al., , 1998 Phillips et al., 1997; Yamasaki et al., 1996) . To test for E2F1 induced apoptosis, COS cells were cotransfected with an E2F1 expression plasmid, and a plasmid expressing the CD20 cell surface antigen (a ratio of 3 : 1 for E2F1 : CD20 ensured that all CD20 positive cells expressed the E2F1 transgene). The cells were subsequently ®xed 48 h after cotransfection, and incubated with both a FITC conjugated anti CD20 antibody, and propidium iodide to stain DNA. Flow cytometry was then performed and the cells were sorted based on CD20 expression. Apoptotic peaks were measured for both the transfected cells (E2F1 expressing and CD20 positive) as well as the non-transfected cells (non-E2F1 expressing and CD20 negative). Figure 3 shows that the levels of apoptosis in cells expressing E2F1 did not dier from the apoptosis levels of cells transfected with empty vector, which was signi®cantly lower than the positive control of cells expressing caspase 8beta. This data indicates that E2F1 is not inducing apoptosis in these COS cells. In addition, the cells expressing E2F1d103 or E2F1(1 ± 139) did not undergo any increase in apoptosis ( Figure 3 ). An additional assay for apoptosis was also performed. COS cells were transfected with either pcDNA3 vector control or E2F1 expressing vector, prepared for indirect immuno¯uorescence, and the DNA was counterstained with DAPI as in Figure  1d . The altered morphology of apoptotic cells is well de®ned (Hann et al., 1998) . Transfected (¯uorescence Figure 3 Ectopic expression of E2F1 does not induce apoptosis in COS cells. COS cells were transfected with empty vector (pcDNA3), with the E2F1 expression plasmid, with plasmids expressing E2F1 mutants E2F1d103 or E2F1(1 ± 139), or a plasmid expressing caspase 8beta along with a plasmid expressing the human CD20 cell surface antigen. A ratio of 3 : 1 for the expression plasmid : CD20 plasmid was used to ensure that all CD20 positive cells expressed the transgene. Forty-eight hours after transfection these cells were ®xed in 0.1% paraformaldehyde, incubated with a FITC conjugated anti-CD20 monoclonal antibody, and stained with propidium iodide. The CD20 positive cells were separated from the CD20 negative cells by¯ow cytometry/cell sorting. The percentage of apoptotic cells in each group was determined as those cells with less than 2N DNA content and is indicated in the ®gure. Error bars represent standard deviation of the mean from multiple experiments Figure 4 Inhibition of plasmid DNA replication is not restricted to COS cells. Phoenix cells were transfected with empty vector (pcDNA3), with the E2F1 expression plasmid or with plasmids expressing E2F1 mutants E2F1d103 or E2F1(1 ± 139). Plasmid isolation, Southern blotting, and densitometry of autoradiographs were carried out as in Figure 1 . Shown is the quantitation of the average relative level (%) of replicated plasmid as determined by densitometry of autoradiographs from multiple experiments. pcDNA3 levels were arbitrarily set at 100%. Error bars represent the standard deviation of the mean positive) cells were analysed for apoptosis. E2F1 caused no increase in apoptosis when compared to the vector control or non-transfected cells (data not shown). Therefore, the reduction in the level of replication of the pcDNA3-E2F1 plasmid in COS cells is not due to induction of apoptosis.
The inhibitory effect of the N terminus of E2F1 on DNA replication of plasmids is not limited to COS cells
The above data indicate that the N terminus of E2F1 inhibits plasmid replication in COS cells. To determine if this inhibitory eect was cell type speci®c, another cell line expressing the SV40 large T antigen was also tested. The empty vector pcDNA3, or the E2F1, E2F1d103, and E2F1(1 ± 139) plasmids (all containing the SV40 origin of replication) were transfected into the Phoenix cell line (a derivative of 293 cells), and the replication assay was performed as in Figure 1 . Shown in Figure 4 , the E2F1 and E2F1(1 ± 139) plasmids have signi®cantly diminished replication levels as compared to empty vector. The E2F1d103 plasmid expressing an N terminal deletion mutant of E2F1 replicated to levels similar to those of backbone plasmid. These results in Phoenix cells are therefore consistent with the data from COS cells, in that the N terminus of E2F1 has an inhibitory function in DNA replication, and E2F1 constructs lacking the N terminal region lose this function.
E2F1 does not act in trans to affect initiation at the SV40 origin of replication
Since the N terminus of E2F1 inhibits replication, it is possible that it does so by aecting events at the origin. To test this possibility, the E2F1 expression plasmid was transfected into COS cells as before, along with a pBluescript plasmid carrying the SV40 origin of replication cloned within the multiple cloning site. This pBluescript-SV40ori' plasmid is able to replicate in COS cells. Both the pBluescript-SV40ori and the E2F1 expression plasmids were tested for replication capacity as in Figure 1 . The autoradiography from these experiments is shown in Figure 5a . While the E2F1 plasmid shows an inhibition of replication, the cotransfected pBluescript-SV40ori plasmids replicated to the same level, regardless of the presence of wild type or mutant E2F1, as quantitated in Figure 5b . This data indicates that wild type E2F1 does not act in trans on another SV40 origin to inhibit replication within the same cell, but must act on some other factor(s) or at some other DNA site to inhibit replication.
In a further eort to determine how E2F1 disrupts DNA replication events, canonical E2F1 binding sites (in one, two, or three copies) were cloned adjacent to the SV40 origin in the pBluescript-SV40ori plasmid to test the hypothesis that E2F1 binding to a plasmid could inhibit the replication of that plasmid. These E2F1 binding site plasmids were cotransfected along with the pcDNA3-E2F1 expression plasmids, and levels of DNA replication for both the`pBluescript-SV40ori-E2F1site' plasmids and pcDNA3 plasmids were monitored as in Figure 5a . The results of this experiment mirrored those of Figure 5 . The presence of E2F1 did not aect the replication of the pBluescript-SV40ori plasmids containing the canonical E2F1 binding sites. In addition, the plasmids with the E2F1 sites replicated to the same levels as plasmids without the sites, regardless of the presence of E2F1 (data not shown). Therefore the inhibition of replication seen above does not appear to be due to canonical binding of the E2F1 transcription factor to DNA.
As an additional control, this experiment was repeated using pcDNA3, cotransfected with the Quantitation of the average relative levels (%) of replicated pBluescript-SV40ori and pcDNA3 plasmids were determined by densitometry of autoradiographs from multiple experiments. Levels of pBluescript-SV40ori plasmid and pcDNA backbone were set at 100%. Error bars represent the standard deviation of the mean. (c) Cotransfections were carried out as in a, using pcDNA3 plasmid instead of the pBluescript-SV40ori plasmid along with one of the E2F1 expressing constructs (E2F1, E2F1d87, or E2F1d103). Plasmid isolation, Southern blotting, and densitometry of autoradiographs were carried out as in Figure 1 . Shown is a representative autoradiograph of a Southern blot. The arrow points to the position of E2F1. (d) Quantitation of the average relative levels (%) of pcDNA3 plasmid replication was determined by densitometry of autoradiographs from multiple experiments. Levels of pcDNA3 plasmid that were cotransfected with the E2F1 expressing plasmid were arbitrarily set at 100%. Error bars represent the standard deviation of the mean pcDNA3-E2F1 plasmid. Figure 5c and d show the results of this experiment, where both wild type and mutant E2F1 show no eect on replication of the cotransfected pcDNA3 plasmid. In total, these data indicate that E2F1 does not aect initiation of replication at the origin of either pBluescript-SV40ori or pcDNA3.
The 3' end of the E2F1 cDNA contains a replication inhibitory sequence From the data above it is clear that the N terminus of E2F1 inhibits DNA replication by acting through a DNA sequence contained within the E2F1 cDNA. Thus, both the N terminus of the E2F1 protein and Figure 6 The N terminus of E2F1 protein inhibits plasmid replication through a cis-acting DNA sequence found in the E2F1 cDNA. (a) The diagram outlines the dierence between the E2F1(1 ± 139) and the 5'E2F1 constructs. Both constructs produce the same mutant E2F1 protein consisting of the N terminal 139 amino acid residues, however the E2F1 1 ± 139 plasmid contains the entire E2F1 cDNA with an inserted stop codon terminating translation after amino acid residue 139. While the 5'E2F1 plasmid does not contain any of the E2F1 cDNA sequence 3' to the region coding for the N terminal 139 amino acid residues of E2F1. (b) Immunoblots. Nuclear extracts were generated from cells transfected with the indicated expression constructs. The extracts were electrophoresed by SDS ± PAGE, immunoblotted and the blots incubated with M2 antibody. The blots were washed, incubated with a secondary alkaline phosphatase conjugated antibody and processed for staining using the Protoblot kit from Promega. Shown in the ®gure are the developed blots indicating expression of the transgenes. (c) COS cells were transfected with empty vector (pcDNA3), or the E2F1, E2F1(1 ± 139), or 5'E2F1 expression plasmids. Plasmid isolation, Southern blotting, and densitometry of autoradiographs were carried out as in Figure 1 . Shown is a representative autoradiograph of a Southern blot. (d) Quantitation of the average relative levels (%) of replicated plasmid was determined by densitometry of autoradiographs from multiple experiments. pcDNA3 levels were set at 100%. Error bars represent the standard deviation of the mean the E2F1 cDNA sequence are necessary for replication inhibition, which appears to be independent of the SV40 origin. To determine where the cis-acting inhibitory element is located within the E2F1 cDNA in more detail, transfections were done using plasmids expressing only the N terminus of the E2F1 protein, with or without the 3' cDNA sequence. These constructs are outlined in Figure 6a . The E2F1, E2F1(1 ± 139), and 5'E2F1 plasmids all express the N terminus of E2F1. The E2F1(1 ± 139) plasmid expresses the ®rst 139 amino acids of E2F1, but contains the entire E2F1 cDNA; the introduction of a stop codon between bases 411 and 412 of the E2F1 cDNA leads to a block in translation. The 5'E2F1 plasmid also expresses the same 139 amino terminal residues as the E2F1(1 ± 139) plasmid, but does not contain any E2F1 cDNA sequence 3' to the stop codon. In this way, these two plasmids express the same N terminal E2F1 peptide yet one contains the entire cDNA sequence while the other does not. These plasmids were then transfected into COS cells. Figure 6b shows an immunoblot of the extracts of transfected cells revealing the level of expression of each protein. Next, following a separate set of transfections with these plasmids, a plasmid replication assay was performed as in Figure 1 . Figure 6c shows the plasmid replication levels by autoradiograph which are quantitated in Figure 6d . The E2F1(1 ± 139) plasmid shows signi®cantly decreased replication levels similar to those of the wild type E2F1 expressing plasmid. However, the 5'E2F1 plasmid replicates to levels similar to those of control pcDNA3 plasmid. It therefore appears that the N terminus of the E2F1 protein may be working through a DNA sequence that is 3' to the stop codon at nucleotide 411.
The N-terminus of E2F1 can inhibit replication in trans from a separate plasmid containing the 3' region of the E2F1 cDNA
As shown above, inhibition of plasmid DNA replication is brought about through the action of the N terminus of the E2F1 protein acting on the 3' end of the E2F1 cDNA. In order to determine if the N terminus of E2F1 can inhibit plasmid replication in a trans-acting fashion, the following experiment was performed. COS cells were transfected with the 5'E2F1 and the E2F1REV plasmids, either individually or together. The 5'E2F1 plasmid expresses only the N terminal 139 amino acid residues of E2F1 and does not contain the 3'E2F1 cDNA sequence. The E2F1REV plasmid, in contrast, contains the entire E2F1 cDNA sequence in the reverse orientation, but does not express any protein. Both plasmids have previously been shown to replicate to optimal levels. When transfected alone, each plasmid replicates to similar high levels, as shown in Figure 7a . However, when cotransfected, the N terminal peptide appears to act in trans to block replication of the E2F1REV plasmid. As shown in Figure 7a , when these plasmids are cotransfected, only the levels of the replicated E2F1REV plasmid are signi®cantly diminished (as quantitated in Figure 7b ), while the 5'E2F1 plasmid expressing the N terminus of E2F1 is relatively unaected. These data indicate that the N terminus of the E2F1 protein can act in trans on the 3'E2F1 cDNA sequence.
The N terminus of E2F1 directs the formation of protein complexes with E2F1 cDNA sequences We have shown above that the E2F1 transcription factor inhibits plasmid DNA replication through speci®c DNA sequences and that the N terminus alone of E2F1 (amino acid residues 1 ± 139) was sucient to bring about this eect. These data lead to the notion that E2F1 was acting in some way through these DNA sequences. To test this idea, electrophoretic mobility (b) Quantitation of the average relative levels (%) of replicated plasmid was determined by densitometry of autoradiographs from multiple experiments. 5'E2F1 levels were arbitrarily set at 100%. Error bars represent the standard deviation of the mean. The levels of`Cotransfected 5'E2F1' and`Cotransfected E2F1REV' refer to the amounts of each plasmid in lane 3 of a shift (gel shift) assays were used to investigate the role of E2F1 in protein complex formation with DNA sequences within the E2F1 cDNA. The portions of the E2F1 cDNA to be used in the gel-shift assay are outlined in Figure 8a . The E2F1 cDNA was divided into three parts, each roughly 400 basepairs in length, which were subsequently end-labeled and used in standard gel-shift assays with COS cell nuclear extracts. The extracts were derived from COS cells transiently transfected with either the vector control (pcDNA3), or with the E2F1 or E2F1(1 ± 139) expression vectors. While E2F1 retains the ability to bind consensus E2F1 DNA binding sites, E2F1(1 ± 139) has no inherent DNA binding ability, since it completely lacks the DNA binding domain.
The results of the gel shift assays are shown in Figure 8b . Probe #1 and #2 show similar band shift patterns, where extracts from cells expressing either E2F1 and E2F1(1 ± 139) lead to the formation of comparable protein : DNA complexes. These data indicate that binding sites exist on both probe #1 and #2 for protein complexes that the formation of these complexes appear to be directed by the N terminus of E2F1. Since E2F1(1 ± 139) lacks the DNA binding domain, it must rely on another protein (or proteins) to bind DNA. (b) Gel-shift assay. COS cells were transfected with pcDNA3, E2F1 or E2F1(1 ± 139) expression plasmids. Forty-eight hours after transfection, the cells were harvested and nuclear extracts were generated. For each reaction, 5 mg of transfected COS nuclear extracts were incubated with 3.5 mg sheared salmon sperm DNA (a non-speci®c competitor), 15 ml D buer (16% glycerol, 20 mM Tris pH 7.9, 80 mM KCl, 1 mM EDTA, 1 mM DTT), and radiolabeled DNA probe, as outlined in a, (5000 c.p.m./reaction) for 20 min at room temperature. The reactions were then electrophoresed in individual lanes of a low ionic strength 4% acrylamide gel (6.7 mM Tris pH 8.0, 1 mM EDTA, 3.3 mM NaOAc, 4% acrylamide for 4 h at 0.25 ± 0.375 V/cm 2 . The buer was changed every 30 min to prevent changes in pH. The gel was then dried and autoradiography of the dried gel is shown. The arrows point to the protein : DNA complexes An additional DNA sequence from the 5' end of the E2F1 cDNA (probe #3) was also included in the gelshift reactions with transfected COS nuclear extracts, to ensure that any binding seen in the above experiment was not due to general DNA binding factors from the COS extracts. Based on the experiments outlined above, E2F1 did not inhibit DNA replication through a 5' cDNA sequence. Therefore, a protein-DNA interaction was not expected to form when`Probe #3' (Figure 8a ) was used in the gel-shift assay. The autoradiograph from this experiment is shown in Figure 8b . Neither E2F1 nor E2F1(1 ± 139) expressing COS nuclear extracts were able to cause a shift with this control probe. In total, these data indicate that the 3' portion of the E2F1 cDNA contains sequences at two dierent sites (i.e. in probe #1 and 2) that are required for protein binding, mediated by the amino-terminus of E2F1.
E2F1 and its N terminal domain affect COS cell genomic DNA replication in distinct ways
While it appears that full length E2F1 and just the amino-terminal domain of E2F1 both inhibit episomal DNA replication in COS cells, it was important to determine their eects on genomic replication. To test this, COS cells were transfected with E2F1 and E2F1(1 ± 139) expression plasmids and cotransfected with a CD20 surface marker expression plasmid. As a control an E2F1d103 expression plasmid was also transfected. At 48 h post transfection the cells were processed for cell sorting and¯ow cytometry. Plasmid ratios were adjusted to ensure that E2F1, E2F1d103 and E2F1(1 ± 139) expression occurred in all CD20 positive cells. Flow cytometry performed the CD20 positive cells revealed that when compared to cells transfected with a pcDNA3 expression vector, there is a large increase in the number of S phase cells expressing the E2F1d103 protein (Figure 9 ). This was expected since this protein causes a partial block at the S phase checkpoint when expressed in cells (Krek et al., 1995; Logan et al., 1995) . However, E2F1 caused a large increase in the percent cells in G2/M while E2F1(1 ± 139) only caused a marginal increase in the percent cells in G2/M phase compared to the control cells. These data indicate that E2F1 and E2F1(1 ± 139) have distinct eects on genomic DNA replication and that full-length E2F1 seems to have a more potent eect, causing the greater change in cell cycle distribution by shifting the percent in G2/M phase.
Discussion
E2F1 has been reported to mediate an S phase checkpoint (Krek et al., 1995) through a mechanism that may involve its interaction with DNA. Here we present evidence that the E2F1 transcription factor can directly in¯uence DNA replication, independent of any induction of apoptosis. The data are consistent with previous studies where the N terminal domain of E2F1 has been shown to aect S phase progression in ®broblasts (Logan et al., 1994 (Logan et al., , 1995 . The inhibitory region of E2F1 appears to be located within its most N terminal 59 amino acids and does not require other functional domains, such as the cyclin A/cdk2 binding domain, the dimerization domain, the DNA binding domain, or the transactivation domain.
While few interactions between the ®rst 59 amino acid residues of the E2F1 protein and other cellular proteins are known that might help to explain the role of this domain in replication, we have identi®ed two cDNAs whose products interact with the N terminus of E2F1. Binding assays revealed that these proteins (termed EBP1 and EBP2 for E2F1 Binding Protein 1 and 2) associate with the N terminal-most 87 amino acid residues of E2F1, and both EBP1 and EBP2 were able to repress transcription from an E2F1 driven promoter (Jordan et al., 1996) . Recently, interactions were also demonstrated between this region of E2F1 and the ubiquitin-protein ligase SCF SKP2 , leading to the ubiquitin-mediated proteolysis of E2F1 (Marti et al., 1999) . Although EBP1, EBP2, and SCF SKP2 interact with E2F1, the relevance of these interactions with regard to E2F1 mediated DNA replication inhibition is still unclear. It may also be possible that E2F1 interacts with as yet unde®ned proteins whose functions are more speci®cally aimed toward DNA replication. In this regard, our data indicates that the E2F1(1 ± 139) protein, which by itself cannot bind DNA, is part of a multi-protein DNA binding complex when expressed in cells in that it is able to bind two distinct regions of the E2F1 gene. We do not yet know the components of this protein complex, but it may be that when bound to DNA it impedes the movement of the DNA replication machinery. Since our results suggest that E2F1 interferes with the elongation stage of DNA synthesis, this inhibitory DNA binding complex may also aect proteins necessary for replication elongation such as Topoisomerase I, or the processivity factors PCNA, RF-C, and DNA Polymerase d, resulting in an inhibition of their activity, and leading to the block in DNA replication.
Control of an S phase checkpoint may lie in this ability of E2F1 to regulate elongation of DNA synthesis, since we ®nd that the N terminus of E2F1 is not functioning to inhibit initiation of replication at the SV40 origin. This was demonstrated by cotransfections in which E2F1 did not inhibit replication of other plasmids such as pBluescript containing an SV40 origin or the pcDNA3 vector. What is most surprising is that the cis-acting DNA sequence aected by E2F1 is found within the E2F1 cDNA. Cotransfection of a plasmid coding for and expressing only the ®rst 139 amino acids of E2F1 (5'E2F1) acted in trans to inhibit replication of a plasmid containing an E2F1 cDNA sequence in the opposite orientation (E2FREV). This indicated that the N-terminus of E2F1 targeted a DNA sequence within the E2F1 cDNA. These data would suggest that the target DNA sequence is located more in the 3' end of the E2F1 cDNA and are in keeping with the results of the gel0shift assay that show E2F1 directs protein complex formation to two distinct regions at the 3' end of the E2F1 cDNA. Identi®cation of this exact sequence will be essential if we are to understand how the checkpoint functions within the mammalian cell cycle.
The cis-acting inhibitory DNA sequence found in the E2F1 cDNA could be present at important locations throughout the mammalian genome, and may represent the sites through which the S phase checkpoint functions. Under conditions of DNA damage for example, where DNA replication would need to be slowed or stopped for repair, the signal for such an S phase checkpoint activation could take place through E2F1, which would act as a replication elongation inhibitor at well-de®ned DNA target sequences. Since a link between DNA damage and E2F1 upregulation has been reported (Blattner et al., 1999) it is possible that E2F1 is directly responsible for monitoring S phase transit during conditions of DNA damage. It may also be possible that E2F1 would halt replication in the event of low nucleotide pools brought on by a change in cellular metabolism (e.g. under conditions of hypoxia). In this case the E2F1 complex would halt DNA replication at the speci®c sites in the genome until it was energetically favorable for the cell to resume the cell division process.
It is also possible that the replication control by E2F1 seen here re¯ects regulation (or inhibition) of replication of extrachromosomal DNA elements such as occurs following viral infection. This could be a potential mechanism to prevent the uncontrolled replication of viral DNA. However, regardless of whether this is a mechanism to control viral or genomic DNA synthesis, a signaling pathway leading to the replication blockage must also exist. As it is a putative checkpoint pathway, cyclins are likely involved, possibly cyclin A/cdk2, which is generally thought to be the active S phase cyclin/cdk complex. Cyclin A/cdk2 could act through the proteins that associate with the N terminal domain of E2F1. It is also possible that an E2F1 block to DNA replication is a downstream event of an established S phase checkpoint pathway such as the ATM/BRCA1 mediated pathway (Cortez et al., 1999; Deng and Brodie, 2000; Li et al., 2000) . It is now important that we de®ne both the cellular factors that interact with the N terminal domain of E2F1 to inhibit replication elongation and the DNA sequence through which they act. Once these are identi®ed, the detailed mechanism underlying this E2F1-mediated replication block will be better understood.
Materials and methods
Cell culture/transfections
COS, transformed African Green Monkey kidney cells, and Phoenix cells (ATCC) were maintained in Dulbecco's modi®ed Eagle's medium (DMEM) supplemented with 10% bovine calf serum. Transfections into COS and Phoenix cells were performed by CaPO 4 methods followed by a glycerol shock (Ausubel et al., 1991) . Thirty mg of plasmid was used in each experiment. For cotransfections, 15 mg of each transfected plasmid was used. Cells were harvested 48 h after transfection for Southern, apoptosis, and immuno¯uores-cence analyses.
Plasmid constructs
The full-length human E2F1 cDNA sequence, and DNA sequences of E2F1 mutants were cloned into the pcDNA3 expression vector (Invitrogen). All E2F1 constructs were epitope tagged by cloning the FLAG epitope sequence in frame, 5' to the translational start site in the E2F1 cDNA sequences. The E2F1D24 construct was a generous gift from Dr Wilhelm Krek, and was previously HA epitope tagged. The pBluescript-SV40ori plasmid was constructed by excising the SV40 origin of replication from the SV40 promoter/ enhancer region of the pSV-bgal plasmid (Promega) by EcoRI/HindIII digestion. This sequence was directionally cloned into the multiple cloning site of pBluescript KS+ (Stratagene).
Flow cytometry
Cell cycle distribution and apoptosis were measured by cotransfecting COS cells with a plasmid expressing the human CD20 cell surface antigen. Forty-eight hours after transfection, cells were removed from tissue culture plates with 1% EDTA, pelleted, and ®xed in 0.1% paraformaldehyde for 20 min on ice. The cells were then rinsed in 10 ml phosphate buered saline (PBS). Cells were than incubated in a solution of 180 ml of 2% Fetal Calf Serum (FCS) in DMEM and 20 ml FITC conjugated anti-human CD20 monoclonal antibody (PharMingen). The cells were then washed in 2% FCS in DMEM, and pelleted. This was followed by resuspension of the cells in 180 mg/ml RNase A in PBS. After a 30 min incubation at room temperature, propidium iodide was added to a ®nal concentration of 1.5 mg/ml. Flow cytometry was then performed. The number of transfected cells in each cell cycle phase and undergoing apoptosis was determined.
Isolation of plasmid DNA/Southern blots
Plasmids were extracted and puri®ed from COS cells 48 h after transfection by method of Hirt (Hirt, 1967) . For Southern analysis, 2 mg of plasmid DNA was digested with both HindIII (Promega) and DpnI (NEB) for 1 h. DpnI digests all methylated DNA (i.e. input non-replicated DNA). The digestion products were run on 0.8% agarose gels and blotted onto nylon membrane (MSI). Blots were probed with 10 6 CPM/ml of [a 32 P]dCTP (NEN) labelled pcDNA3 plasmid.
Immunofluorescence COS cells were plated on 10 cm tissue culture plates containing sterile glass coverslips. The cells were transfected with either an empty vector control (pcDNA3) or with the indicated E2F1 expression plasmids. Forty-eight hours after transfection, cells were washed with PBS, then ®xed with 4% paraformaldehyde in PBS for 20 min, followed by an additional rinse in PBS. To permeabilize the cell membranes, the coverslips were treated with PBS plus 0.2% Triton X-100 for 15 min followed by three washes with PBS plus 0.2% gelatin (Harlow and Lane, 1988) . The antiFlag M2 monoclonal antibody (Kodak) or an anti-HA monoclonal antibody (Promega) for E2F1D24 was diluted to 50 ng/ml in PBS plus 0.2% gelatin. Fifty ml of diluted antibody was added to a 6 cm tissue culture plate, coverslips containing the ®xed permeabilized cells were placed cell side down on the drop of diluted antibody and incubated for 1.5 h at 378C (Logan et al., 1994) . The coverslips were washed three times in PBS plus 0.2% gelatin. Fluorescein-conjugated goat antimouse IgG (Vector Laboratories) was diluted to 30 mg/ml in PBS plus 0.2% gelatin. Again 50 ml of diluted antibody were placed in a tissue culture plate, and the coverslips placed cell side down on the antibody for 30 min at 378C. The coverslips were washed twice in PBS plus 0.2% gelatin. The DNA of the cells were then stained with 2 ml of a 0.5 mg/ml solution of 4',6-diamidino-2-phenylindone (DAPI). The coverslips were then rinsed three times in PBS and then once in deionized water. Coverslips were then dried, mounted, and analysed by¯uorescence microscopy.
Immunoblotting
For immunoblotting, the proteins in the nuclear extracts were electrophoretically resolved by SDS ± PAGE (40 mg protein/ lane) and transferred onto nitrocellulose ®lters. The blots were then washed in TBST buer (10 mM Tris, pH 8; 150 mM NaCl; 0.05% Tween 20), blocked with 2.5% bovine serum albumin (BSA) in TBST for 30 min at room temperature and incubated with the primary antibody (antiFLAG M2 monoclonal antibody) for 60 min at room temperature in TBST. The blots were then washed three times, 10 min each, in TBST. The blots were then incubated with 1 : 7500 dilution of secondary antibody conjugated to alkaline phosphatase (goat anti-mouse, Santa Cruz Biotech), for 30 min at room temperature in TBST. The blots were then processed for detection using the protoblot kit from Promega.
Protein extraction for gel shift assays
Cells isolated for protein extraction were scraped from 100 mm tissue culture plates (Falcon) 48 h post transfection into 5 ml PBS, and pelleted by centrifugation at 500 g for 5 min at 48C. Nuclear extracts were generated by lysing the harvested cells on ice in 0.1% NP-40, 10 mM Tris (pH 8.0), 10 mM MgCl 2 , 15 mM NaCl, PMSF (0.5 mM), pepstatin (2 mg/ml), and leupeptin (1 mg/ml) for 10 min. The nuclei were isolated by centrifugation at 5000 g for 5 min and the supernatant is termed`cytosolic fraction'. The nuclei were then resuspended on ice in 0.42 M NaCl, 20 mM HEPES (pH 7.9), 20% glycerol, PMSF (0.5 mM), pepstatin (2 mg/ml), and leupeptin (1 mg/ml) for 10 min, followed by centrifugation at 12 000 g for 10 min to pellet residual nuclear material. This supernatant was termed the`nuclear extract'.
Electrophoretic mobility shift (gel shift) assay
The puri®ed DNA probe (*5 ng) was end-labeled with 32 P using 2 units of T4 Polynucleotide Kinase (Promega) 2 ml 106kinase buer (Promega), g-labeled 32 P ATP (300 mCi used from a 6610 6 Ci/mol per reaction) in a 20 ml reaction by incubating at 378C for 1 h. Unincorporated 32 P ATP was cleared from labeled probe by passing the reaction through the G25 Sephadex spin column (Roche) spun at 500 g for 5 min. For each reaction, 5 mg transfected COS nuclear extracts were incubated with 3.5 mg sheared salmon sperm DNA (a non-speci®c competitor), D buer (16% glycerol, 20 mM Tris pH 7.9, 80 mM KCl, 1 mM EDTA, 1 mM DTT), and radiolabeled DNA probe (5000 c.p.m./reaction) for 20 min at room temperature. The reactions were then electrophoresed in individual lanes of a low ionic strength 4% acrylamide gel (6.7 mM Tris pH 8.0, 1 mM EDTA, 3.3 mM NaOAc) for 4 h at 0.25 ± 0.375 V/cm 2 . The buer was changed every 30 min to prevent pH changes detrimental to native protein structure. The gel was then dried onto Whatman paper, and imaging is performed by autoradiography of the dried gel.
